Moreover, it has been demonstrated that activating mutations at the Y641 amino acid in the EZH2 gene within the EZH2 catalytic SET domain are frequent in DLBCL and more effective at producing a repressed transcriptional state [11,12]; as a result, there is an increasing interest in developing selective EZH2 inhibitors as a target therapy in lymphomas and other tumors [15]. Here, EZH2 is linked to lymphoma.